The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The Department of the Army Medical Command awarded a $1,000,000 project grant to Duke University's Office of Research Administration Division under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 1, 2024 and running through May 31, 2027, will fund a practical multi-domain risk model of Alzheimer's disease and related dementias for veteran and non-veteran older U.S. adults. The research project aims to improve the health and care of military service...
The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...
The Defense Health Agency awarded Duke University a $483,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of March 1, 2021 through February 28, 2024. The grant funding will support Duke University's research project "Targeting Glutamine Utilization in Therapy-Resistant Prostate Cancer." The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research...
The federal Project Grant award of $481,158.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) enables Duke University to conduct research aimed at "Blocking Glutamine Utilization in Advanced and Therapy-Resistant Prostate Cancer." The award supports a two-year project from June 1, 2024 to May 31, 2026 to expand the frontiers of scientific knowledge and apply it to address a critical medical challenge facing military service...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The Defense Health Agency awarded Duke University a $804,999 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research on "DETECTING MISSED METASTASES FROM NOMINALLY EARLY-STAGE MELANOMAS WITH PUMP-PROBE MICROSCOPY". The award runs from September 1, 2023 to August 31, 2026. The Project Grant enables Duke's research to transform health care for Service Members and the American public through innovative and impactful biomedical research...
This $241,500.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program will support research at Duke University to investigate the "UNDERSTANDING THE MOLECULAR COMMUNICATION BETWEEN PROSTATE CANCER CELL TYPES." The award period runs from September 1, 2025 to August 31, 2027. As a leading private research university, Duke University has a robust track record of securing federal grants and contracts...
Duke University was awarded a $931,969 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 to develop epigenetic signatures to predict pathological nodal stage for de-escalation of axillary surgery in patients with clinically node-positive breast cancer. The research aims to transform patient care by investigating medical solutions that could help reduce the need...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...